Clinical trials
Muscle-Invasive Bladder Carcinoma clinical trials
Below are recruiting muscle-invasive bladder carcinoma clinical trials, each written for real people, not researchers. We’re tracking 59 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06170177Recruiting
Life after bladder removal surgery study
This study looks at how people feel and their health after having their bladder removed. It aims to understand quality of life after this surgery.
Milan, MIAges 18 years+ - NCT06215976RecruitingPhase 4
Metformin with cisplatin for bladder cancer: protecting kidneys
This trial tests if adding metformin to cisplatin chemotherapy can protect the kidneys of people with bladder cancer. It may help reduce kidney damage from cisplatin treatment.
CairoAges 18–65 - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT06287541Recruiting
Do you need a second bladder surgery after a negative urine test?
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
Nanjing, JiangsuAges 18 years+ - NCT06341400RecruitingPhase 1/Phase 2
Combination drug treatment before bladder cancer surgery
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06417190RecruitingPhase 2
Bladder preservation trial for muscle-invasive bladder cancer with variant histology
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT06470282RecruitingPhase 1/Phase 2
Drug combo plus radiation for muscle-invasive bladder cancer
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
San Francisco, CaliforniaAges 18 years+ - NCT06493552RecruitingPhase 2/Phase 3
Testing sEphB4-HSA in EphrinB2-high bladder cancer
This trial tests a new drug called sEphB4-HSA for people with a specific type of bladder cancer (urothelial carcinoma) that has high levels of a protein called EphrinB2. The study aims to see if this drug can shrink tumors or prevent them from growing, and it compares it to standard treatments like chemotherapy or immunotherapy.
Santa Monica, CaliforniaAges 18 years+ - NCT06503614RecruitingPhase 2
Durvalumab and monalizumab for early bladder cancer
This trial tests two drugs—durvalumab and monalizumab—for people with early-stage bladder cancer that hasn't spread into the muscle and has persisted or returned after BCG treatment. The goal is to see if this combination can control the cancer and delay or avoid the need for bladder removal surgery.
Tampa, FloridaAges 18 years+ - NCT06537154RecruitingPhase 2/Phase 3
Neoadjuvant therapy for bladder cancer with active surveillance
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
Vancouver, British ColumbiaAges 19 years+ - NCT06537960Recruiting
Later scan images to better see bladder cancer spread
This trial tests whether taking extra, later images during your standard FDG PET-CT scan can give doctors a better view of how far your muscle-invasive bladder cancer has spread. You may be eligible if you are 18 or older, have confirmed muscle-invasive bladder cancer, and are already getting this type of scan.
Suresnes, Île-de-France RegionAges 18 years+ - NCT06571708RecruitingPhase 2
Chemo plus immunotherapy for muscle-invasive bladder cancer
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
New York, New YorkAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT07302230Recruiting
Home exercise app for bladder cancer patients
This trial tests whether a home-based physical activity program using a smartphone app helps people with non-muscle invasive bladder cancer become more active compared to a health education group. It's designed for those who are not very active and want to improve their health.
Seattle, WashingtonAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT07122414RecruitingPhase 1/Phase 2
Testing a new drug for bladder cancer that resists BCG
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07130578Recruiting
Urine DNA test to guide second bladder cancer surgery
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
TianjinAges 18 years+ - NCT07180212Recruiting
Urine DNA Test to Guide Cystoscopy in High-Risk Bladder Cancer
This trial tests a urine test that looks for tumor DNA to help doctors decide when you need a cystoscopy (a scope in the bladder). It is for people with high-risk or very high-risk non-muscle-invasive bladder cancer who have already had surgery to remove all visible tumors.
Xingtai, HebeiAges 18 years+ - NCT07225127Recruiting
Bladder cancer treatment: therapy vs. surgery
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
Tampa, FloridaAges 18 years+ - NCT07234968Recruiting
Stent vs no stent after bladder removal surgery
This study looks at whether leaving a small tube (ureteral stent) in place after bladder removal helps recovery. It compares people who get a stent to those who don't, focusing on problems like leaks or infections after surgery.
Philadelphia, PennsylvaniaAges 18–85 - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for muscle-invasive bladder carcinoma?
- Yes. Clin2 currently lists 59 recruiting muscle-invasive bladder carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a muscle-invasive bladder carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a muscle-invasive bladder carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Recurrent Non-Muscle Invasive Bladder Carcinoma
- Non Muscle Invasive Bladder Cancer
- Muscle Invasive Bladder Cancer (MIBC)
- Non-Muscle Invasive Bladder Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.